vanflyta
daiichi sankyo europe gmbh - quizartinib dihydrochloride - leukemija, myeloid, akutna - antineoplastična sredstva - zdravljenje akutno mieloično levkemijo.
vanflyta
daiichi sankyo europe gmbh - quizartinib dihydrochloride - leukemija, myeloid - antineoplastic agents, protein kinase inhibitors - vanflyta is indicated in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by vanflyta single-agent maintenance therapy for adult patients with newly diagnosed acute myeloid leukaemia (aml) that is flt3-itd positive.
xalkori
pfizer europe ma eeig - krizotinib - karcinom, pljučni pljuč - antineoplastična sredstva - xalkori as monotherapy is indicated for:the first‑line treatment of adults with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc)the treatment of adults with previously treated anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc)the treatment of adults with ros1‑positive advanced non‑small cell lung cancer (nsclc)the treatment of paediatric patients (age ≥6 to.
lorviqua
pfizer europe ma eeig - lorlatinib - karcinom, pljučni pljuč - antineoplastic agents, protein kinase inhibitors - lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. lorviqua as monotherapy is indicated for the treatment of adult patients with alk‑positive advanced nsclc whose disease has progressed after:alectinib or ceritinib as the first alk tyrosine kinase inhibitor (tki) therapy; orcrizotinib and at least one other alk tki.
alecensa
roche registration gmbh - alectinib hidroklorid - karcinom, pljučni pljuč - antineoplastična sredstva - alecensa kot monotherapy je določen za prvo linijo zdravljenja odraslih bolnikih z anaplastični limfom kinaza (alk)-pozitivno napredno non-small cell lung cancer (nsclc). alecensa kot monotherapy je indiciran za zdravljenje odraslih bolnikov z alkalno‑pozitivno napredno nsclc predhodno zdravljenih z crizotinib.
zykadia
novartis europharm limited - ceritinib - karcinom, pljučni pljuč - antineoplastična sredstva - zdravilo zykadia je indicirano za zdravljenje odraslih bolnikov z anaplastičnim limfom-kinaznim (alk) pozitivnim napredovalim nedrobnoceličnim pljučnim rakom (nsclc), ki je bil predhodno zdravljen s krizotinibom.
irinotekanijev klorid kabi 20 mg/ml koncentrat za raztopino za infundiranje
fresenius kabi austria gmbh. - irinotekan - koncentrat za raztopino za infundiranje - irinotekan 17,33 mg / 1 ml - irinotekan
irinotekan accord 20 mg/ml koncentrat za raztopino za infundiranje
accord healthcare - irinotekan - koncentrat za raztopino za infundiranje - irinotekan 17,33 mg / 1 ml - irinotekan
irinotekan accord 20 mg/ml koncentrat za raztopino za infundiranje
accord healthcare - irinotekan - koncentrat za raztopino za infundiranje - irinotekan 17,33 mg / 1 ml - irinotekan
irinotekan accord 20 mg/ml koncentrat za raztopino za infundiranje
accord healthcare - irinotekan - koncentrat za raztopino za infundiranje - irinotekan 17,33 mg / 1 ml - irinotekan